A Study on the Treatment Strategy of NVG Secondary to PDR (NCT05156021) | Clinical Trial Compass
CompletedNot Applicable
A Study on the Treatment Strategy of NVG Secondary to PDR
China39 participantsStarted 2021-12-12
Plain-language summary
With the increasing incidence of proliferative diabetic retinopathy (PDR), subsequent neovascular glaucoma (NVG) has become one of the main causes of blindness in PDR patients, and the intraocular pressure of PDR patients with NVG is often stubborn. For these patients, not only is the effect of drugs in lowering intraocular pressure poor, but the results of surgery are often unsatisfactory. Because of its poor prognosis, clinical research for better strategy is of great significance in the current situation. At present, for such patients, a combination of effective control of intraocular pressure and treatment of the primary disease is often used. The purpose of this study was to investigate the clinical effects of preoperative with/without intraoperative anti-vascular endothelial growth factor (VEGF) drug therapy combined with pars plana vitrectomy (PPV), pan-retinal photocoagulation (PRP), and pressure-reducing valve implantation in patients with NVG secondary to PDR. Furthermore, the changes of neurotrophic factors in the vitreous humor before and after anti-VEGF treatment will be explored.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* male or female patients aged over 18 years diagnosed with type 1 or 2 diabetic mellitus (DM) confirmed by experienced endocrinologists. Active PDR and NVG was clinically evident across these patients. The indications to perform surgery included vitreous hemorrhage or fibrous proliferation in the macular area, together with uncontrolled intraocular pressure.
Exclusion Criteria:
* (i) coexistent ocular disease that may interfere with visual outcome; (ii) previous history of vitrectomy or anti-VEGF pharmacotherapy in either eye; (iii) a macula-involving retinal detachment for \>6 months in the study eye; (iv) severe external ocular infection; (v) usage of anticoagulant or antiplatelet therapy; (vi) preoperative or postoperative poor diabetes control \[serum hemoglobin A1c (HbA1c) \>11.0%\]; (vii) uncontrolled systemic diseases, such as hypertension, cardiac diseases or presenting abnormal coagulation-associated blood diseases.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study looked at neovascular glaucoma caused specifically by proliferative diabetic retinopathy — does my situation match that closely enough that the findings might be relevant to my care?
2The trial tracked best corrected visual acuity and intraocular pressure over 12 months after surgery — based on my current vision and eye pressure, what kind of changes would my doctor consider a meaningful improvement or a warning sign?
3Since this study is now completed, has my doctor seen its results, and do those results change how they'd recommend treating my neovascular glaucoma compared to what they'd have suggested before?
4The study is listed as 'Phase NA,' meaning it wasn't a standard drug trial with phased safety testing — can my doctor explain what type of surgical approach was being studied and whether it's already used in routine care or still considered experimental?
5Are there standard treatments for neovascular glaucoma from proliferative diabetic retinopathy that I should consider first, and how does the treatment strategy explored in this trial compare to those options in terms of evidence and risk?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Changes in Best Corrected Visual Acuity from baseline to 12 months after surgery
Timeframe: Follow-up on the first day, first week, 1, 3, 6, 9 and 12 months after surgery
2
Changes in Intraocular Pressure from baseline to 12 months after surgery
Timeframe: Follow-up on the first day, first week, 1, 3, 6, 9 and 12 months after surgery